{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T07:28:50Z","timestamp":1769844530844,"version":"3.49.0"},"reference-count":21,"publisher":"Japanese Society of Internal Medicine","issue":"21","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2017]]},"DOI":"10.2169\/internalmedicine.8638-16","type":"journal-article","created":{"date-parts":[[2017,9,24]],"date-time":"2017-09-24T22:08:06Z","timestamp":1506290886000},"page":"2895-2898","source":"Crossref","is-referenced-by-count":8,"title":["Afatinib Therapy for Brain Metastases Aggravated by a Reduction in the Dose of Erlotinib Due to the Development of Hepatotoxicity"],"prefix":"10.2169","volume":"56","author":[{"given":"Yumie","family":"Yamanaka","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Japan"},{"name":"Department of Respiratory Medicine, Tokyo Jikei University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akimasa","family":"Sekine","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terufumi","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Yamakawa","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Japan"},{"name":"Department of Respiratory Medicine, Tokyo Jikei University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohisa","family":"Baba","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae","family":"Iwasawa","sequence":"additional","affiliation":[{"name":"Department of Radiology, Kanagawa Cardiovascular and Respiratory Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Okudela","sequence":"additional","affiliation":[{"name":"Department of Pathology, Graduate School of Medicine, Yokohama City University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Ogura","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Iuchi T, Shingyoji M, Sakaida T, et al. Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma. Lung Cancer 82: 282-287, 2013.","DOI":"10.1016\/j.lungcan.2013.08.016"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Lee YJ, Choi HJ, Kim SK, et al. Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall-cell lung cancer. Cancer 116: 1336-1343, 2010.","DOI":"10.1002\/cncr.24877"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Ricciardi S, de Marinis F. Multimodality management of non-small cell lung cancer patients with brain metastases. Curr Opin Oncol 22: 86-93, 2010.","DOI":"10.1097\/CCO.0b013e3283350106"},{"key":"4","unstructured":"4. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11: 121-128, 2010."},{"key":"5","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.lungcan.2013.07.003","volume":"82","author":"K Goto","year":"2013","unstructured":"5. Goto K, Nishio M, Yamamoto N, et al. A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC). Lung Cancer 82: 109-114, 2013.","journal-title":"Lung Cancer","ISSN":"https:\/\/id.crossref.org\/issn\/0169-5002","issn-type":"print"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Inoue A, Kobayashi K, Usui K, et al. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 27: 1394-1400, 2009.","DOI":"10.1200\/JCO.2008.18.7658"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Toba H, Sakiyama S, Takizawa H, Tangoku A. Safe and successful treatment with afatinib in three postoperative non-small cell lung cancer patients with recurrences following gefitinib\/erlotinib-induced hepatotoxicity. J Med Invest 63: 149-151, 2016.","DOI":"10.2152\/jmi.63.149"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Ueda H, Hayashi H, Kudo K, Takeda M, Nakagawa K. Successful treatment with afatinib after gefitinib- and erlotinib-induced hepatotoxicity. Invest New Drugs 34: 797-799, 2016.","DOI":"10.1007\/s10637-016-0384-1"},{"key":"9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2016.05.002","volume":"99","author":"Y Zenke","year":"2016","unstructured":"9. Zenke Y, Umemura S, Sugiyama E, et al. Successful treatment with afatinib after grade 3 hepatotoxicity induced by both gefitinib and erlotinib in EGFR mutation-positive non-small cell lung cancer. Lung Cancer 99: 1-3, 2016.","journal-title":"Lung Cancer","ISSN":"https:\/\/id.crossref.org\/issn\/0169-5002","issn-type":"print"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Ling J, Johnson KA, Miao Z, et al. Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers. Drug Metab Dispos 34: 420-426, 2006.","DOI":"10.1124\/dmd.105.007765"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Stopfer P, Marzin K, Narjes H, et al. Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers. Cancer Chemother Pharmacol 69: 1051-1061, 2012.","DOI":"10.1007\/s00280-011-1803-9"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31: 3327-3334, 2013.","DOI":"10.1200\/JCO.2012.44.2806"},{"key":"13","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.lungcan.2015.01.026","volume":"88","author":"M Takeda","year":"2015","unstructured":"13. Takeda M, Okamoto I, Nakagawa K. Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer. Lung Cancer 88: 74-79, 2015.","journal-title":"Lung Cancer","ISSN":"https:\/\/id.crossref.org\/issn\/0169-5002","issn-type":"print"},{"key":"14","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.resinv.2016.06.007","volume":"54","author":"K Kashiwabara","year":"2016","unstructured":"14. Kashiwabara K, Semba H, Fujii S, Tsumura S. Tolerability and efficacy of afatinib at a low starting dosage in 10 elderly or low performance status patients with advanced refractory non-small-cell lung cancer. Respiratory investigation 54: 468-472, 2016.","journal-title":"Respiratory Investigation","ISSN":"https:\/\/id.crossref.org\/issn\/2212-5345","issn-type":"print"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Bai H, Han B. The effectiveness of erlotinib against brain metastases in non-small cell lung cancer patients. Am J Clin Oncol 36: 110-115, 2013.","DOI":"10.1097\/COC.0b013e3182438c91"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Deng Y, Feng W, Wu J, et al. The concentration of erlotinib in the cerebrospinal fluid of patients with brain metastasis from non-small-cell lung cancer. Mol Clin Oncol 2: 116-120, 2014.","DOI":"10.3892\/mco.2013.190"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 21: 2237-2246, 2003.","DOI":"10.1200\/JCO.2003.10.038"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290: 2149-2158, 2003.","DOI":"10.1001\/jama.290.16.2149"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Lampson BL, Nishino M, Dahlberg SE, et al. Activity of erlotinib when dosed below the maximum tolerated dose for EGFR-mutant lung cancer: Implications for targeted therapy development. Cancer 2016 (Epub ahead of print).","DOI":"10.1002\/cncr.30270"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Hoffknecht P, Tufman A, Wehler T, et al. Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease. J Thorac Oncol 10: 156-163, 2015.","DOI":"10.1097\/JTO.0000000000000380"},{"key":"21","unstructured":"21. Yang JC, Sequist LV, Zhou C, et al. Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials. Ann Oncol 27: 2103-2110, 2016."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/56\/21\/56_8638-16\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,18]],"date-time":"2020-10-18T05:19:21Z","timestamp":1602998361000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/56\/21\/56_8638-16\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":21,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.8638-16","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}